Patent Grant
12171867
The invention pertains generally to topical treatments containing copper ions and to methods of making topical treatments containing copper oils for use in treating conditions in various anatomical areas of the body. More particularly, the invention pertains to topical treatments containing copper ions and to methods of making such topical treatments wherein copper ions from copper metal are leached into a solution.
Many various abnormal body conditions are caused by harmful pathogens or microbes, examples of which include bacteria, fungi and viruses. Abnormal body conditions that arise in or affect the genital area in women typically affect the vagina and are commonly referred to as “vaginitis”. The term “vaginitis” encompasses infection and/or inflammation of the vagina caused by bacteria, fungi and/or viruses. Vaginitis may extend to the external female genital area, i.e. the vulva, in which case it is usually referred to as “vulvovaginitis”. In addition, bacterial, fungal and viral conditions that affect all or part of the genital area in women, i.e. vagina, vulva and/or surrounding anatomical area, may also affect all or part of the rectal (anal) area, i.e. the rectum (anal canal) and surrounding anatomical area. In men, infection and/or inflammation of bacterial, fungal and/or viral origins may affect all or part of the rectal area and also all or part of the genital area, i.e. the penis, scrotum and surrounding anatomical area.
Vaginitis that is bacterial in origin is commonly called “bacterial vaginosis”. Many different bacteria are responsible for bacterial vaginosis and some of these bacteria are the cause of sexually transmitted diseases in women and men. Examples of sexually transmitted bacterial diseases that affect the vagina and surrounding an areas are gonorrhea and chlamydia, which appear in the general population on a widespread basis. It is estimated by the Centers for Disease Control and Prevention (CDC) that more than 700,000 people annually in the U.S. alone acquire new gonorrhea infections. According to the CDC, over 1.3 million chlamydia infections were recorded in the U.S. in 2010 alone. In addition, there are a large number of undiagnosed, untreated or unreported infections of gonorrhea and chlamydia because the diseases may be asymptomatic or present with only very mild symptoms. Oftentimes, gonorrhea and chlamydia occur together. Gonorrhea and chlamydia may also appear in the mouth, throat and rectum (anus) in men and women. If left untreated, gonorrhea and chlamydia can spread to the uterus and/or Fallopian tubes and may cause pelvic inflammatory disease (PID) infertility, ectopic pregnancies, chronic pelvic pain and increased risk for infection with the human immunodeficiency virus (HIV). Untreated gonorrhea may also affect the blood, joints and heart valves. The usual treatments for gonorrhea and chlamydia are appropriate antibiotics, but history has demonstrated that over time many bacterial diseases develop a resistance to antibiotics. Indeed, according to the CDC, numerous antibiotics previously used to treat gonorrhea have lost their effectiveness, and there is currently only one remaining drug, i.e. the injectable antibiotic ceftriaxone, proven effective for treating gonorrhea. There is great concern in the medical community that it is only a matter of time before gonorrhea becomes resistant to this last remaining drug. Other types of pathogens and microbes, such as the bacteria streptococcus and staphylococcus and the parasitic protozoan trichomonas, may also affect the vagina and surrounding anatomical areas resulting in abnormal biological conditions. As with gonorrhea, staphylococcus infections are especially problematic because certain strains of the bacteria have become antibiotic resistant. Infections in the vagina may spread to the uterus, resulting in PID which is often a very painful and serious condition with potentially harmful and permanent complications.
In addition to being susceptible to abnormal body conditions caused by bacteria, the vagina and surrounding anatomical areas are susceptible to various abnormal body conditions caused by viruses and fungi. Viral diseases that arise in or affect the vagina and surrounding anatomical areas include herpes (Types I and II), human papilloma virus (HPV) and HIV, all of which are sexually transmittable. Herpes, HPV and HIV can also be found in the areas of the mouth, skin and rectum (anus). Fungal diseases that arise in or affect the vagina include yeast infections, particularly candida, and thrush. Fungi are also responsible for abnormal biological conditions in other areas of the body such as the mouth (thrush), feet, skin and nails. There is no cure for herpes and HIV. Anti-viral drugs are available to alleviate herpes symptoms and suppress the herpes virus so that active infections recur less frequently and are of shorter duration, but these drugs are associated with significant side effects. Infection with HPV is usually treated with topical medications, oral medications and/or surgical removal of warts. Complications of HPV infection include increased risk for cervical, rectal and vulvar cancers. Available treatments for HIV are designed to suppress the virus and boost the immune system in hope of avoiding opportunistic infections and delaying or preventing the onset of full-blown acquired immune deficiency syndrome (AIDS). In recent years, it was hoped that a vaginal microbicide gel called PRO 2000 would be effective at reducing HIV infection when used shortly before sexual intercourse, but unfortunately the compound was found to be ineffective in a large scale clinical trial. Topical and oral medications are available to treat yeast and other fungal infections but are limited in effectiveness such that fungal infections are often not eradicated and thus reoccur. The vast majority of abnormal body conditions caused bacteria, viruses and fungi that affect the genital and/or rectal areas in women also affect the genital and/or rectal areas in men.
In addition to conditions caused by harmful pathogens or microbes, hemorrhoids are another abnormal body condition that affects the rectum (anus) in men and women and may cause rectal pain, swelling, discomfort and/or itching. Conventional treatments for hemorrhoids include topical medications and surgery. In addition to harmful microbes and pathogens, sperm are microbes that appear in the vagina after intercourse. Numerous spermicidal contraceptive compounds are available for introduction in the vagina. Typically, these must be introduced in the vagina very shortly before intercourse and are therefore oftentimes inconvenient. When intercourse takes place without contraception and there is concern for an unwanted pregnancy, drugs known as the “morning after pill” or “emergency contraceptives” are sometimes prescribed to prevent pregnancy, but these drugs are not 100% effective and may have undesirable side effects.
Abnormal body conditions of bacterial, viral and fungal origins commonly arise in dermatological areas of the body, i.e. skin and nails. The skin and soft tissue are common sites for infections caused by various bacteria including staphylococcus, enterobacter, pseudomonas, and streptococcus. Oftentimes, infections develop on the skin at the site of a cut, scratch, abrasion, burn, splinter, boil, pimple, blister, insect bite or other wound or trauma that damages or breaks the skin or provides a point of entry for bacteria and/or other harmful organisms. Viruses such as herpes, shingles and HPV are also the cause of abnormal body conditions on the skin. In particular, herpes causes cold sores (fever blisters), shingles causes painful eruptions, and HPV causes warts on the skin. Other organisms also cause warts on the skin. The skin is susceptible to various fungal conditions, such as “athlete's foot” which commonly occurs on the feet and rashes such as ringworm. Infections of the nails, particularly fungal infections of the toenails, are also a common and tenacious problem. The skin is further susceptible to various body conditions resulting from aging, environmental factors and various external and internal causes, such conditions including sun/wind damage, dry skin, age spots, pigmentation, scarring, blisters, boils, cysts, pimples, cuts, scratches, burns, abrasions, splinters, insect bites and stings, animal bites and scratches, ulcers, loss of elasticity or collagen that manifests as winkles and sagging skin, acne, and many types of rashes, such as measles, chicken pox, eczema, psoriasis, impetigo and rosacea, due to various underlying external and internal causes. Various topical and oral prescription and non-prescription medications and products are available to treat the foregoing skin conditions. The skin is also a carrier for bacteria, viruses and fungi, seeing as how the skin regularly comes in contact with a plethora of pathogens and microbes. Consequently, many products such as sanitizing hand and body lotions and wipes are available commercially for the purpose of reducing germs on the skin.
The oral-respiratory-otic areas of the body, i.e. mouth, throat, nose, sinuses and ears are also common sites for abnormal body conditions due to the aforementioned pathogens and microbes. In addition, various allergies cause undesirable body conditions that impact the oral-respiratory-otic areas of the body, particularly the throat, nose and sinuses. Asthma is a chronic inflammatory disease of the airways responsible for undesirable conditions. Bacteria, viruses, fungi, allergies and/or asthma are responsible for many unwanted symptoms that appear in the oral-respiratory-otic areas of the body including sore throat, tonsillitis, colds, bronchitis, sinusitis, rhinosinusitis, wheezing, ear infections, earache, pressure in the ears, cold sore, mouth ulcers, canker sores, cough, hoarseness or laryngitis, congestion, runny nose, sneezing, sore gums, periodontal disease, tooth decay and halitosis (bad breath). A vast array of prescription and non-prescription drugs and products are commercially available to treat oral-respiratory-otic conditions.
The prescription drugs and even many of the non-prescription drugs or products used to treat the numerous body conditions described above have many drawbacks including undesirable or potentially harmful side effects, high risk of harm in the event of overdose or improper use, high cost, limited effectiveness, the need for close medical monitoring, and inconvenience. Moreover, there is presently no single compound or product to treat a wide range of body conditions affecting the genital-rectal areas that include the vagina, rectum (anus), and surrounding anatomical areas, oral-respiratory-otic areas that include the mouth, throat, airway, nose, sinuses and ears, and the dermatological areas that include the skin and nails, much less a non-pharmaceutical topical treatment that is safe, cost-effective, easy and convenient to use, and capable of being embodied in different forms depending on the intended anatomical area or areas of use.
It has previously been established that copper possesses properties by which it is capable of killing, neutralizing and preventing the growth of human pathogens. It is known that many bacteria identified as human pathogens cannot survive on surfaces of copper metal U.S. Pat. No. 8,135,466 B2 to Fuller et al discloses a joint prosthesis having an implant body with an external surface containing an antimicrobial metal where the antimicrobial metal may be copper. U.S. Patent Application Publications No. US 2012/0071807 A1 and No. US 2012/0089068 A1 to McClure, Jr. disclose wound dressings containing a metal-based antimicrobial agent where the metal-based antimicrobial agent may be a mixture of silver ions and copper ions. Devices having an external surface of copper metal for insertion in the vagina to treat abnormal biological conditions have been proposed by Applicants in U.S. patent application Ser. No. 12/157,823 filed Jun. 13, 2006 (abandoned), Ser. No. 13/317,230 filed Oct. 12, 2011, and Ser. No. 13/464,005 filed May 4, 2012, the entire disclosures of which are incorporated herein by reference.
Topical substances containing particles of copper or its alloys have been proposed for health support uses. A product called “MesoCopper®” sold by Purist Colloids, Inc. is a colloidal copper solution containing nano particles of copper for use on the skin to minimum the appearance of fine lines and wrinkles. Another version of the product is sold as an ingestible mineral supplement. Copper peptides for use on the skin are also commercially available and these require peptides, i.e. small fragments of protein that have an affinity for copper to which they bind very tightly, U.S. Pat. No. 7,716,915 B2 to Morariu discloses a topical composition containing, at a minimum, a lipoic acid, a carnitine and a carnosine, where the carnosine may be chelated to zinc or copper ions. The intended use for the topical composition is to improve the appearance of aged skin, U.S. Patent Application Publication No. US2008/0195033 A1 to Eagleson et al discloses use of a metal substance to treat diseases in the body. The metal substance is primarily a colloidal suspension and delivery of the substance to the body may require the use of electricity. Prior to the present invention, it has not been recognized to provide a simple solution containing copper ions for use as a topical treatment to be applied directly to anatomical tissue to treat body conditions and/or for use in conjunction with various carriers including creams, gels, lotions, foams, pastes, other solutions, suppositories, tampons, body wipes, wound dressings, skin patches and suture material to form topical treatments in which the carriers facilitate delivery of the copper ions to contact anatomical tissue depending on the anatomical area or areas of use on the body.
According to an aspect of the invention, a topical copper ion treatment is prepared by a process whereby copper ions from copper metal leach into a biocompatible solution. The copper metal in solid form is placed into the solution in a sealed vessel, and the sealed vessel is placed in an oven to heat or maintain the solution at a temperature equal or substantially equal to 37° Celsius for a predetermined period of time during which copper ions leach from the copper metal into the solution. After the period of time has expired, the solution is separated from the copper metal and constitutes a copper ion-containing solution that can be used as a copper ion treatment for topical application to anatomical tissue in various areas of the body to treat various body conditions. Preferably, the biocompatible solution is a saline solution and the copper metal is pure copper. A copper ion-containing solution obtained in accordance with a preferred process results in en amount of copper ions equal or substantially equal to 46 mg present in 7.44 ounces of the copper ion-containing solution.
The copper ion-containing solution can be combined with various carriers to facilitate application or delivery of the copper ion-containing solution to anatomical tissue in accordance with the anatomical area or areas of use. Suitable carriers include creams, lotions, gels, foams, pastes, other solutions, tampons, suppositories, body wipes, wound dressings, skin patches and suture material to obtain other forms of copper ion treatments. Various devices such as containers, bottles and tubes can be used to dispense the copper ion treatments in a manner best suited for the form of copper ion treatment and/or the intended anatomical area or areas of use. The copper ion treatments are particularly advantageous for use on anatomical tissue of the genital-rectal areas, the oral-respiratory-otic areas and the dermatological areas of the body.
A solution maintaining copper ions, i.e. copper ion-containing solution, for use as a topical treatment containing copper ions, i.e. topical copper ion treatment, to treat body conditions is produced according to a process or method by which copper ions from copper metal are leached into an appropriate biocompatible solution. As used herein, “copper metal” means pure copper (99.5% or greater copper after processing) and copper alloys such as brasses, bronzes, copper-nickels and copper-nickel-zincs. Preferably, pure copper is used as the copper metal. Example 1 describes the steps involved in producing an amount of copper ion-containing solution equal or substantially equal to 7.44 ounces.
7.44 ounces of biocompatible saline solution buffered with acetic acid and sodium acetate to a pH of 5 (±0.4) is placed in a container or vessel with a tight, removable lid to minimize evaporation. The container is placed in an incubator or oven at a temperature of 37° Celsius (±1° C.). When the saline solution has reached 37° Celsius, 102 grams of pure copper metal in solid form is placed in the heated solution within the container, and the container with the tight lid thereon is placed in the incubator at 37° Celsius for 24 hours. During the 24 hour period, copper ions from the copper metal leach into the solution. At the end of the 24 hour period, the container is removed from the incubator and the copper metal is removed or separated from the solution. The amount of solution remaining after removal or separation of the cooper metal therefrom constitutes the copper ion-containing solution and should be essentially 7.44 ounces with minimal evaporation. The copper ion-containing solution produced according to this process contains copper ions an amount equal or substantially equal to 46 milligrams when analyzed for copper content by inductively coupled plasma/optical emission spectroscopy (ICP/OES). The copper ion-containing solution is stored at room temperature and is ready for use it this form as a topical copper ion treatment to be applied to anatomical tissue to treat body conditions. In addition, the copper ion-containing solution is ready for use in conjunction with various carriers including creams, gels, lotions, foams, pastes, other solutions, suppositories, tampons, body wipes, wound dressings, skin patches and suture materials to form topical copper ion treatments in which the carriers facilitate delivery of the copper, ion treatments to contact anatomical tissue to treat body conditions.
The solid pure copper metal in Example 1 may be in the form of one or more sheets of pure copper metal, typically in the range of 0.03 to 0.06 inch thick, of appropriate length and width to provide the 102 grams of pure copper metal. In practice, the process described in Example 1 has been carried out using as the copper metal four vaginal therapeutic devices made of pure copper in accordance with Applicants' prior patent application Ser. No. 13/464,005 previously incorporated herein by reference in its entirety. In this case, each vaginal therapeutic device used was 3.25 inches long by 0.750 inch wide with a wall thickness of 0.031 inch providing 25.5 grams of pure copper. The biocompatible saline solution used in the process described in Example 1 is commercially available from B. Braun Medical. As an alternative to the biocompatible saline, vaginal simulating fluid (VSF) buffered with acetic acid to a pH of 5 (±0.4) can be used as the biocompatible solution, but will produce less leaching of copper ions from copper metal over the 24 hour period. The VSF can be prepared in accordance with published literature, e.g. Owen, D. H., Katz, D. F., “A Vaginal Fluid Simulant”, Contraception, pages 94-95 (1999). The process described in Example 1 can be modified to eliminate the step of heating the solution prior to placement of the copper metal therein. In the latter case, the copper metal and unheated solution are placed in the container, the container with the tight lid thereon is placed in the incubator at 37° Celsius and, once the solution has reached 37° Celsius, the container with the heated solution and copper metal therein is allowed to remain in the oven for 24 hours. The copper metal can be removed or separated from the solution in various ways, such as by lifting the metal out of the solution or pouring the solution alone into another container. Of course, the quantities of biocompatible saline and solid copper mental used in Example 1 can be proportionately increased to produce a greater amount of copper ion-containing solution with each process.
The copper ion-containing solution is believed to have the greatest effectiveness for treating a wide range of body conditions when the solution contains the amount of copper ions leached into the saline from the copper metal over a 24 hour period as described in Example 1. However, it should be appreciated that the process described in Example 1 can be modified to obtain lower copper ion concentrations by adjusting the length of time that the container containing the heated saline and copper metal is allowed to remain in the incubator or oven as explained below in Examples 2, 3 and 4.
Follow the steps of Example 1 but allow the container containing the saline and copper metal to remain in the oven at 37° C. for one hour to obtain a copper ion-containing solution that contains an amount of copper ions equal or substantially equal to 8.8 mg.
Follow the steps of Example 1 but allow the container containing the saline and copper metal to remain in the oven at 37° C. for eight hours to obtain a copper ion-containing solution that contains an amount of copper ions equal or substantially equal to 22 mg.
Follow the steps of Example 1 but allow the container containing the saline and copper metal to remain in the oven at 37° C. for 72 hours to obtain a copper ion-containing solution that contains an amount of copper ions equal or substantially equal to 35 mg.
The copper ion-containing solution in its original form, i.e. at the end of the processes of Examples 1-4, can be applied directly to anatomical tissue in various anatomical areas of the body as a copper ion treatment to treat various body conditions. Many types of containers or bottles can be used to hold a quantity of the copper ion-containing solution and to dispense or apply the copper ion-containing solution to anatomical tissue in accordance with the intended anatomical area or areas of use. The copper ion-containing solution may also be used in conjunction with various carriers including creams, lotions, gels, foams, pastes, other solutions, tampons, suppositories, body wipes, wound dressings such as band aids and pads, skin patches and suture material to form copper ion treatments that facilitate delivery or application of the copper ion-containing solution, and therefore the copper ions, to anatomical tissue. Creams, lotions, gels, foams a pastes may be used when it is advantageous to alter the consistency of the copper toil-containing solution from its original form to obtain a thicker copper ion treatment to facilitate its delivery or application to anatomical tissue. As a result of the copper ions contacting anatomical tissue when the copper ion treatments are applied thereto, local and systemic therapeutic effects are realized including antibacterial, antimicrobial, antiseptic, antifungal, antiviral, anti-pathogenic, anti-inflammatory, spermicidal neutralization of free radicals, promotion of healing and tissue repair, prevention of biofilm, and immune-boosting effects. In particular, these effects are realized when the copper ion treatments are used on anatomical tissue in the genital-rectal areas, the oral-respiratory-otic areas and the dermatological areas of the body since the anatomical tissue in these areas is favorable for local and systemic delivery of drugs and medicaments.
In accordance with an aspect of the present invention the copper ion-containing solution is combined with an appropriate topical cream base to form a copper ion-containing cream, i.e. copper ion cream in which the amount of copper ion-containing solution is preferably in the range of 5% to 30% by weight of the total weight of the copper ion cream. Examples 5, 6, 7 and 8 pertain to copper ion creams made in accordance with this aspect of the invention using the copper ion-containing solution of Example 1.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical cream base to form a copper ion cream in which the copper ion-containing solution constitutes 5 percent of the total weight of the copper ion cream.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical cream base to form a copper ion cream in which the copper ion-containing solution constitutes 10 percent of the total weight of the copper ion cream.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical cream base to form a copper ion cream in which the copper ion containing solution constitutes 20 percent of the total weight of the copper ion cream.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical cream base to form a copper ion cream in which the copper ion-containing solution constitutes 30 percent of the total weight of the copper ion cream.
Various topical cream blues can be used as the carrier for the copper ion-containing solution in order to form the copper ion creams of Examples 5, 6, 7 and 8. One suitable topical cream base that can be used is VersaBase® cream made by Professional Compounding Centers of America (PCCA) of Houston, Texas Another suitable topical cream base that can be used in the copper ion creams is Vanicream® made by Pharmaceutical Specialties, Inc. of Rochester, Minnesota. The copper ion creams are effective against the body conditions being treated when the only active ingredient in the copper ion creams directed at the underlying condition is the copper ion-containing solution. However, the copper ion creams could contain other ingredients added to the topical meant base that are not active ingredients with respect to the underlying condition being treated such as preservatives, penetrating additives, bioadhesives and stability aids. Preferably, a total weight of at least 70 grams, more preferably 80 grams, of the copper on creams in the various strengths, i.e. 5 percent, 10 percent, 20 percent and 30 percent of copper ion-containing solution relative to the total weight of the copper ion cream, will be provided for use in containers, bottles, or tubes from which the copper ion creams can be dispensed. It should be appreciated that copper ion creams can be made using the alternative copper ion-containing solutions described above.
According to a further aspect of the present invention, a topical copper ion treatment in the form of a copper ion-containing gel, i.e. copper ion gel, is composed of the copper ion-containing solution and a suitable topical gel base as illustrated below by Examples 9, 10, 11 and 12, which utilize the copper ion-containing solution of Example 1. The amount of the copper ion-containing solution in the copper ion gel is preferably in the range of 5% to 30% by weight of the total weight of the copper ion gel.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical gel base to form a copper ion gel in which the copper ion-containing solution constitutes 5 percent of the total weight of the copper ion gel.
An appropriate amount of copper ion-containing solution is combined with biocompatible topical gel base to form a copper ion gel in which the copper ion-containing solution constitutes 10 percent of the total weight of the copper ion gel.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical gel base to form a copper ion gel in which the copper ion-containing solution constitutes 20 percent of the total weight of the per ion gel.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical gel base to form a copper ion gel in which the copper ion-containing solution constitutes 30 percent of the total weight of the copper ion gel.
Various topical gel bases can be used as a carrier for the copper ion-containing solution in order to form the copper ion gels. An example of a suitable topical gel base that can be used in Examples 9-12 is VersaBase® gel made by PCCA. As explained above for the copper on creams, the copper ion gels will be effective when the only active ingredient in the copper ion gels is the copper ion-containing solution, but other ingredients that are inactive with respect to the underlying condition being treated can be added to the topical cream gels. Preferably, a total weight of at least 70 grams, more preferably 80 grams, of the copper ion gels in the various strengths, i.e. 5 percent, 10 percent, 20 percent and 30 percent of copper ion-containing solution relative to the total weight of the copper on gel, is provided for use in containers, bottles or tubes from which the copper ion gels can be dispensed. Also, copper ion gels can be made using the alternative copper ion-containing solutions. Copper ion gels can be made having a thin, fluidic consistency, and such gels may be used as copper ion serums.
A topical copper ion treatment in the form of a copper ion-containing lotion, i.e. copper ion lotion, according to an additional aspect of the invention is composed of the copper ion-containing solution and a suitable topical lotion base as represented by Examples 13, 14, 15 and 16. Examples 13-16 employ the copper ion-containing solution of Example 1, but copper ion lotions could be made using the alternative copper ion-containing solutions. The amount of the copper ion-containing solution in the copper ion lotion is preferably in the range of 5% to 30% by weight of the total weight of the copper ion lotion. Copper ion gels can be made having a thin fluidic consistency, and such gels may be used as copper ion serums.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical lotion base to form a copper ion lotion in which the copper ion-containing solution constitutes 5 percent of the total weight of the copper ion lotion.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical lotion base to form a copper ion lotion in which the copper ion-containing solution constitutes 10 percent of the total weight of the copper ion lotion.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical lotion base to form a copper ion lotion in which the copper ion-containing solution constitutes 20 percent of the total weight of the copper ion lotion.
An appropriate amount of copper ion-containing solution is combined with biocompatible topical lotion base to form a copper ion lotion in which the copper ion-containing solution constitutes 30 percent of the total weight of the copper ion lotion.
Various topical lotion bases can be used as a carrier for the copper ion-containing solution in the copper ion lotions of Examples 13-16. One suitable topical lotion base that can be used is VersaBase® lotion made by PCCA. As explained above for the copper ion creams and gels, the copper ion lotions will be effective against the body conditions being treated when the only active ingredient in the copper ion lotions is the copper ion-containing solution, but other inactive ingredients could be added to the topical lotion base. Preferably, a total weight of at least 70 grams, more preferably 80 grams, of the copper ion lotions in the various strengths, i.e. 5 percent, 10 percent, 20 percent and 30 percent of copper ion-containing solution relative to the total weight of the copper ion lotion, will be provided for use in containers, bottles or tubes from which the copper ion lotions can be dispensed.
According to another aspect of the present invention, a topical copper ion treatment in the form of a copper ion-containing foam, i.e. copper ion foam, is composed of the copper ion-containing solution and a suitable foam base. Examples 17, 18, 19 and 20 set forth below pertain to copper on foams or foamable solutions made in accordance with this aspect of the invention using the copper ion-containing solution of Example 1, however copper ion foams or foamable solutions can be made using the alternative copper ion-containing solutions. The amount of the copper ion-containing solution in the copper ion foam or foamable solution is preferably in the range of 5% to 30% by weight of the total weight of the copper ion foam or foamable solution.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical foam base to form a copper ion foam or foamable solution in which the copper ion-containing solution constitutes 5 percent of the total weight of the copper ion foam or foamable solution.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical foam base to form a copper ion foam or foamable solution in which the copper ion-containing solution constitutes 10 percent of the total weight of the copper ion foam or foamable solution.
An appropriate amount of copper ion-containing solution is combined with a biocompatible to foam base to form a copper ion foam or foamable solution in which the copper ion-containing solution constitutes 20 percent of the total weight of the copper ion foam or foamable solution.
An appropriate amount of copper ion-containing solution is combined with a biocompatible topical foam base to form a copper ion foam or foamable solution in which the copper ion-containing solution constitutes 30 percent of the total weight of the copper ion foam or foamable solution.
Various topical foam bases can be used as a caller for the copper ion-containing solution in order to form the copper ion foams or foamable solutions. Depending on the foam base used in Examples 17-20, the combination of foam base and copper ion-containing solution may be in the form of a foam. Alternatively, some foam bases that may be used will result in a foamable solution when combined with the copper ion-containing solution, and the foamable solutions will typically require an appropriate dispenser to create the actual foam. An example of a suitable topical foam base that can be used is VersaBase® foam made by PCCA. When using VersaBase® as the foam base in Examples 17-20, a foamable solution is obtained and requires a foam dispenser to create the foam. As explained above for the copper ion creams, gels and lotions, the copper ion foams will be effective against the body conditions being treated with the only active ingredient therein being the copper ion-containing solution. However, other ingredients that are inactive with respect to the condition being treated can be added to the topical foam base. It is preferred that a total weight of at least 70 grams, more preferably 80 grams, of the copper ion foams or foamable solutions in the various strengths, i.e. 5 percent, 10 percent, 20 percent and 30 percent of copper ion-containing solution relative to the total weight of the copper ion foam or foamable solution, be provided in dispensers from which the copper ion foams can be dispensed.
According to a further aspect of the invention, a topical copper ion treatment in the form of a copper ion-containing paste, i.e. copper ion paste, is composed of the copper ion-containing solution and a suitable paste base. Example 21 set forth below pertains to a copper ion toothpaste made in accordance with this aspect of the invention using the copper ion-containing solution of Example 1, but copper ion pastes can also be made using the alterative copper ion-containing solutions. The amount of the copper ion-containing solution in the copper ion pastes is preferably in the range of 5% to 30% by weight of the total weight of the copper on paste.
An appropriate amount of copper ion-containing solution is combined with a toothpaste base material to form a copper on toothpaste in which the copper ion-containing solution constitutes in the range of 5 percent to 30 percent of the total weight of the copper on toothpaste.
The toothpaste base material used in Example 21 can be a commercially available toothpaste including any of the toothpastes marketed and sold under the major brand names. A toothpaste made in accordance with Example 21 is advantageous for treating bad breath, sore gums, gum disease and tooth decay when used on a daily basis in place of a person's regular toothpaste.
According to a further aspect of the invention, the copper ion-containing solution can be combined with various base solutions to form alternative copper ion solutions. Example 22 set forth below pertains to a copper ion mouthwash made in accordance with this aspect of the invention using the copper ion-containing solution of Example 1, but copper ion solutions can also be made using the alternative copper ion-containing solutions of Examples 2-4. The amount of copper ion-containing solution in the alternative copper ion solution is preferably in the range of 5% to 30% by weight of the total weight of the copper ion solution.
An appropriate amount of copper ion-containing solution is combined with a mouthwash base solution to form a copper ion mouthwash in which the copper ion-containing solution constitutes in the range of 5 percent to 30 percent of the total weight of the copper ion solution.
The mouthwash base solution used in Example 22 can be a commercially available mouthwash including any of the mouthwashes marketed and sold under the major brand names. A mouthwash made in accordance with Example 22 is advantageous for treating bad breath, sore gums, periodontal disease and tooth decay when used on a daily basis.
The examples described above pertaining to carriers in the nature of lotions, gels, foams and other solutions are particularly well suited for creating copper ion treatments in the nature of copper ion soaps by using as carriers lotion, gel, foam or other solution bases containing a soap component. The copper ion soaps could be designed for use as body soaps or as dish soaps.
Another device 20 useful for dispensing the copper ion treatments, particularly the copper ion-containing solution in its original form, is shown in
The device 30 depicted in
An additional device 40 for dispensing the copper ion treatments is shown in
The device 50 illustrated in
The device 70 shown in
Another type of applicator useful in applying the copper ion treatments to anatomical tissue is shown at 101 in
Another type of earner that can be used to deliver copper ion treatments to the vagina is a tampon. The tampon used can be a commercially available tampon or one similar thereto. The tampon can be one having an applicator including a barrel containing the absorbent tampon body and a plunger slidable within the barrel to dispose or eject the absorbent tampon body from an open forward and of the barrel once the forward end has been introduced in the vagina an appropriate distance in a commonly known manner of tampon use. In this case, an appropriate amount of copper ion treatment can be supplied to the absorbent tampon body via the open forward end of the barrel prior to introduction of the applicator the vagina and ejection of the absorbent tampon body from the applicator into the vagina. Another suitable tampon can be one without an applicator, i.e. a digital tampon, where the absorbent tampon body is inserted in the vagina by pushing it with the fingers. In this case, the appropriate amount of copper ion treatment is simply deposited on the absorbent tampon body prior to its insertion in the vagina. In both cases, unless the tampon is going to be inserted in the vagina immediately or soon after the absorbent tampon body has been provided with the appropriate mount of copper ion treatment, the tampon should be stored in a sealed container or package until the time of its use in order to avoid evaporation of the copper ion treatment. It should be appreciated that tampon bodies to which the copper ion treatment has been supplied can be provided in sealed containers or packages, with or without an applicator, as a ready-to-use commercial product. Alternatively, the appropriate amount of copper ion treatment may be deposited by the user on the absorbent tampon bodies of tampons sold separately or in injunction with the copper ion treatment. Preferably, the tampon bodies are supplied with an amount of popper ion-containing solution in the range of 6 to 10 milliliters.
A tampon for delivering a copper ion treatment to the vagina is prepared by supplying 5 milliliters of a copper ion-containing solution to an absorbent tampon body intended to be it into the vagina.
A tampon for delivering a copper ion treatment to the vagina is prepared by supplying 10 milliliters of a copper ion-containing solution to an absorbent tampon body intended to be introduced into the vagina.
The copper ion-containing solution used in Examples 23 and 24 is the copper ion-containing solution in its original form as obtained in accordance with the method set forth in Example 1. However, it should be appreciated that tampons can be provided in which the tampon bodies are supplied with the alternative copper ion-containing solutions or other forms of the copper ion treatments.
Another type of came useful to deliver the copper ion treatments to the vagina and rectum is a suppository. Suppositories are commonly used in the vagina and rectum (anus) as a means for dispensing various active ingredients or medicaments. Suppositories are made in various shapes including oviform, globular, conical and bullet shapes, and in various sizes. Suppositories typically weigh in the range of 1 to 5 grams. Suppositories can be solid bodies composed of a mixture of a suitable suppository base material and the active ingredients or medicaments. Alternatively, suppositories can be made with a solid outer wall of suppository base material enclosing non-solid active ingredients or medicaments. The suppository base materials used in suppositories allow them to dissolve or melt when exposed to the moisture (body fluid) or heat (body temperature) found in the vagina or rectum (rectal or anal canal), thereby releasing the active ingredients or medicaments into the vagina or rectum. Suitable suppository base materials in dude oleaginous (fatty) base materials, including was butter, theobroma oil and synthetic triglycerides, or water soluble or miscible base materials, including glycerinated gelatin and polyethylene glycol (PEG) polymers. It is preferred that the base materials be non-toxic, non-initiating, inert, and biocompatible. Suppositories suitable for use in an aspect of the present invention can be prepared in various ways according to conventional methods for preparing suppositories including compression molding and fusion molding. Suppositories for use as vaginal and rectal suppositories according to an aspect of the present invention are preferably made in two different sizes, i.e. a suppository weighing 3 grams and a suppository weighing 5 grams, to accommodate different sizes of vaginal and rectal anatomy. Each size suppository can be made in different strengths based on the percentage by weight of the active ingredient, i.e. the copper ion treatment, relative to the total weight of the suppository. Preferably, the amount of copper ion-containing solution in the suppository is in the range of 5% to 30% of the total weight of the suppository. The suppositories are preferably formed in plastic molds and can be stored at room temperature. The suppositories will be effective against the body condition being treated when the only active ingredient contained in the vaginal end rectal suppositories is the copper ion treatment. However, the vaginal and rectal suppositories could contain additional in that are inactive with respect to the underlying condition or conditions being treated, such as preservatives, penetrating additives, bioadhesives and stability aids. The suppositories may be inserted in the vagina and rectum using the fingers, or the suppositories may be provided with applicators to facilitate insertion thereof in the vagina and rectum. Examples of vaginal and rectal suppositories according to an aspect of the invention are set forth in Examples 25-32, which utilize the copper ion-containing solution of Example 1. However, the alternative copper ion-containing solutions could be used in Examples 25-32.
A suppository base material is combined with an appropriate amount of copper ion-containing solution and is molded into a suppository for vaginal or rectal use having a total weight of 3 grams, wherein the copper ion-containing solution constitutes 5 percent of the total weight of the suppository.
A suppository base material is combined with an appropriate amount of copper ion-containing solution and is molded into a suppository for vaginal or rectal use having a total weight of 3 grams, wherein the copper ion-containing solution constitutes 10 percent of the total weight of the suppository.
A suppository base material is combined with an appropriate mount of copper ion-containing solution and is molded into a suppository for vaginal or rectal use having a total weight of 3 grams, wherein the copper ion-containing solution constitutes 20 percent of the total weight of the suppository.
A suppository base material is combined with an appropriate amount of copper ion-containing solution and is molded into a suppository for vaginal or rectal use having a total weight of 3 grams, wherein the copper ion-containing solution constitutes 30 percent of the total weight of the suppository.
A suppository base material is combined with an appropriate amount of copper ion-containing solution and is molded into a suppository for vaginal or rectal use having a total weight of 5 grams, wherein the copper ion-containing solution constitutes 5 percent of the total weight of the suppository.
A suppository base material is combined with an appropriate amount of copper ion-containing solution and is molded into a suppository for vaginal or rectal use having a total weight of 5 grams, wherein the copper ion-containing solution constitutes 10 percent of the tot weight of the suppository.
A suppository base material is combined with an appropriate amount of copper ion-containing solution and is molded into a suppository for vaginal or rectal use having a total weight of 6 grams, wherein the copper ion-containing solution constitutes 20 percent of the total eight of the suppository.
A suppository base material is combined with an appropriate amount of copper ion-containing solution and is molded into a suppository for vaginal or rectal use having a total weight of 5 grams, wherein the copper ion-containing solution constitutes 30 percent of the total weight of the suppository.
Another type of carrier that can be used to deliver the copper ion treatments to anatomical tissue is a body wipe.
Another type of carrier for the copper ion treatments is a wound dressing, such as a band aid, gauze pad or similar device. Such carriers can be selected from products that are commercially available for removable application to the skin to temporarily cover and protect an affected area of the skin.
A further type of carrier for the copper ion treatments is a skin patch, such as a dermal patch or a transdermal patch, represented at 400 in
An additional type of owner for the copper ion treatments is suture material, represented at 500 in
The copper ion-containing solution and the other forms of copper ion treatments described herein can be used on anatomical tissue in various areas of the body including the genital-rectal areas (vagina, vulva, penis, scrotum, rectum (anus), rectal (anal) canal and surrounding anatomical areas), the oral-respiratory-otic areas (mouth, throat, airway, nostrils and ears) and the dermatological areas (skin and nails) of the body. The treatment effects provided by the copper ion treatments encompass treatment of active or existing disease and other undesirable body conditions as well as the prevention of such diseases and conditions. The copper on treatments are especially beneficial for their ability to kill or neutralize harmful or undesired pathogens and microbes including bacteria, viruses and fungi. Although the copper on treatments are applied to to anatomical tissue and have a for effect on diseases and undesirable body conditions affecting the anatomical tissue, the copper ion treatments also have a broader systemic effect on diseases and undesirable body conditions. The effects realized with the copper ion treatments include antibacterial, antimicrobial, antiseptic, antifungal, antiviral, anti-pathogenic, anti-inflammatory, spermicidal, neutralization of free radicals, promotion of healing and tissue repair, prevention of and immuno-boosting effects. The diseases or conditions affecting the genital-rectal areas that are treatable with the copper ion treatments include vaginitis, bacterial vaginosis, hemorrhoids, vaginal dryness, imbalances in vaginal pH, bacterial infections caused by gonorrhea, chlamydia, streptococcus and staphylococcus, protozoan infections caused by trichomonas, pelvic inflammatory disease, viral infections caused by herpes (I and II), HPV and HIV, fungal infections caused by yeast, candida, thrush and other fungi, exposure to sexually transmitted diseases, and the risk of undesired pregnancy (contraception). The diseases or conditions affecting the oral-respiratory-otic areas that are treatable with the copper ion treatments include bacterial infections caused by gonorrhea, chlamydia, streptococcus and staphylococcus, protozoan infections caused by trichomonas, viral infections caused by herpes (I and II), HPV and HIV, canker sores, mouth sores, mouth ulcers, colds, sinusitis, rhinosinusitis, sore throat, nasal discharge, congestion, runny nose, bronchitis, allergies, asthma, tonsillitis, wheezing, sneezing, ear infections, earache, pressure in the ears, cough, hoarseness, laryngitis, sore gums, periodontal disease, bad breath and tooth decay. The diseases or conditions affecting the dermatological areas that are treatable with the copper ion treatments include bacterial infections caused by staphylococcus, streptococcus, enterobacter, E. coli and pseudomonas, viral infections caused by shingles, herpes (I and II) and HPV, fungal infections such as athlete's foot, ringworm and toenail fungus, impetigo, rosacea, psoriasis, eczema, warts, sun/wind damage, dry skin, age spots, pigmentation, scarring, blisters, boils, cysts, pimples, cuts, scratches, burns, abrasions, splinters, insect bites and stings, animal bites and scratches, ulcers, loss of elasticity or collagen, wrinkles, sagging skin, acne, measles, chicken pox, and the presence of pathogens and microbes on the skin that is an inevitable consequence of daily life. Based on the result of laboratory testing, it is expected that the copper ion treatments will kill bacteria causing bacterial vaginosis, gonorrhea and chlamydia, and the viruses responsible for herpes (I and II) and HIV at a kill rate of 99.99 percent in 6 hours. Accordingly, the copper ion treatments are sufficiently effective to “cure” the diseases and conditions described herein and to prevent the occurrence or development of such diseases and conditions. Similarly, copper has been demonstrated as having the capability to kill or render inactive staphylococcus, streptococcus, enterobacter, trichomonas, E. coli and pseudomonas. The copper ion treatments are highly effective at treating the various abnormal or undesired body conditions while being safe and non-toxic. In particular, copper toxicity is so rare that the World Health Organization (WHO) has determined that there is no need for setting an upper threshold for the ingestion of copper. The copper ion treatments can thus be safely used without concern for overdosing or improper use. Moreover, it is believed that, to date, no bacteria or other harmful microorganisms have been found to be capable of developing a resistance to copper, in contrast to the many bacteria and organisms that have developed or are in the process of developing resistance to conventional antibiotics. The multi-target effects of copper makes bacterial resistance extremely unlikely as copper kills bacteria very quickly and leaves almost no survivors. Consequently, them is neither the time for bacteria to learn how to resist the killing effect of copper or the possibility to pass on any knowledge to a significant population of survivors. The copper ion treatments provide a degree of efficacy and safety for treating a wide array of diseases and body conditions that far surpasses conventional pharmaceutical and non-pharmaceutical products and drugs available for treating the same conditions.
Inasmuch as the present invention is subject to many variations, modifications and changes in detail it is intended that all subject matter discussed above or shown in the accompanying drawings be interpreted as illustrative only and not be taken in a limiting sense.
This patent application is a continuation of U.S. patent application Ser. No. 13/841,992, filed on Mar. 15, 2013, which is hereby incorporated by reference herein in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2994642 | Bossard | Aug 1961 | A |
| 3393678 | Pacini | Jul 1968 | A |
| 3803308 | Zipper | Apr 1974 | A |
| 3814809 | Gordon | Jun 1974 | A |
| 3930834 | Schulteis et al. | Jan 1976 | A |
| 3934580 | Cournut | Jan 1976 | A |
| 4039406 | Stanley et al. | Aug 1977 | A |
| 4136172 | Walliczek | Jan 1979 | A |
| 4242192 | Dunning, Jr. et al. | Dec 1980 | A |
| 4246896 | Horne, Jr. et al. | Jan 1981 | A |
| 4294894 | Vellucci | Oct 1981 | A |
| 4332791 | Raaf et al. | Jun 1982 | A |
| 4391270 | Uragami | Jul 1983 | A |
| 4407786 | Drake et al. | Oct 1983 | A |
| 4457909 | Tames | Jul 1984 | A |
| 4618489 | Pollock et al. | Oct 1986 | A |
| 4642230 | Whitehead et al. | Feb 1987 | A |
| 4661101 | Sustmann | Apr 1987 | A |
| 4675014 | Sustmann et al. | Jun 1987 | A |
| 4680309 | Maurer | Jul 1987 | A |
| 4795628 | Afseth | Jan 1989 | A |
| 4959216 | Daunter | Sep 1990 | A |
| 5037634 | Williams et al. | Aug 1991 | A |
| 5063065 | Bazterrica et al. | Nov 1991 | A |
| 5164367 | Pickart | Nov 1992 | A |
| 5211940 | Ishiguro et al. | May 1993 | A |
| 5389360 | Mobley et al. | Feb 1995 | A |
| 5415866 | Zook | May 1995 | A |
| 5425862 | Hartmann et al. | Jun 1995 | A |
| 5456602 | Sakuma | Oct 1995 | A |
| 5458746 | Burgess et al. | Oct 1995 | A |
| 5631017 | Sharpe et al. | May 1997 | A |
| 5654341 | Struewing | Aug 1997 | A |
| 5798116 | Brown | Aug 1998 | A |
| 5981475 | Reynolds | Nov 1999 | A |
| 6022545 | Schmittmann et al. | Feb 2000 | A |
| 6042848 | Lawyer et al. | Mar 2000 | A |
| 6087549 | Flick | Jul 2000 | A |
| 6123925 | Barry et al. | Sep 2000 | A |
| 6153210 | Roberts et al. | Nov 2000 | A |
| 6231889 | Richardson et al. | May 2001 | B1 |
| 6294186 | Beerse et al. | Sep 2001 | B1 |
| 6296881 | Hata et al. | Oct 2001 | B1 |
| 6319391 | Holderness et al. | Nov 2001 | B1 |
| 6383352 | Shyu et al. | May 2002 | B1 |
| 6787160 | Shacknai | Sep 2004 | B2 |
| 7005556 | Becker et al. | Feb 2006 | B1 |
| 7087249 | Burrell et al. | Aug 2006 | B2 |
| 7252839 | Hallinen et al. | Aug 2007 | B2 |
| 7604819 | Huey et al. | Oct 2009 | B2 |
| 7776915 | Morariu | Aug 2010 | B2 |
| 7857961 | Hayashi et al. | Dec 2010 | B2 |
| 8118028 | Karpati | Feb 2012 | B2 |
| 8135466 | Fuller et al. | Mar 2012 | B2 |
| 8182800 | MacDonald | May 2012 | B2 |
| 10398733 | Abbott et al. | Sep 2019 | B2 |
| 11000545 | Abbott et al. | May 2021 | B2 |
| 11007143 | Abbott et al. | May 2021 | B2 |
| 11083750 | Abbott et al. | Aug 2021 | B2 |
| 11193184 | Abbott et al. | Dec 2021 | B2 |
| 11253544 | Abbott et al. | Feb 2022 | B2 |
| 11298316 | Abbott | Apr 2022 | B2 |
| 11318089 | Abbott et al. | May 2022 | B2 |
| 11459638 | Abbott et al. | Oct 2022 | B2 |
| 11717535 | Abbott | Aug 2023 | B2 |
| 11857514 | Abbott | Jan 2024 | B2 |
| 20020114767 | Rolla | Aug 2002 | A1 |
| 20020136758 | Jehan | Sep 2002 | A1 |
| 20030099718 | Burrell et al. | May 2003 | A1 |
| 20030163149 | Heisinger | Aug 2003 | A1 |
| 20030166510 | Pickart | Sep 2003 | A1 |
| 20040120908 | Cohen | Jun 2004 | A1 |
| 20040171519 | DiSpirito et al. | Sep 2004 | A1 |
| 20040182694 | Ulderico | Sep 2004 | A1 |
| 20040234457 | Rennie | Nov 2004 | A1 |
| 20040254097 | Patt | Dec 2004 | A1 |
| 20050031707 | Schmidt et al. | Feb 2005 | A1 |
| 20050048007 | Ruggles | Mar 2005 | A1 |
| 20050123620 | Chiou | Jun 2005 | A1 |
| 20050169852 | Roberge et al. | Aug 2005 | A1 |
| 20050226945 | Ruwart | Oct 2005 | A1 |
| 20060122095 | Delvin et al. | Jun 2006 | A1 |
| 20060216258 | Singleton et al. | Sep 2006 | A1 |
| 20060222622 | Faure | Oct 2006 | A1 |
| 20060253078 | Wu et al. | Nov 2006 | A1 |
| 20070014839 | Bracht | Jan 2007 | A1 |
| 20070053849 | Doyle et al. | Mar 2007 | A1 |
| 20070167971 | Huey et al. | Jul 2007 | A1 |
| 20070187327 | George et al. | Aug 2007 | A1 |
| 20070190175 | Cummins et al. | Aug 2007 | A1 |
| 20070243263 | Trogolo | Oct 2007 | A1 |
| 20070275021 | Lee et al. | Nov 2007 | A1 |
| 20070275073 | Huey et al. | Nov 2007 | A1 |
| 20070276308 | Huey et al. | Nov 2007 | A1 |
| 20080029915 | Waldron | Feb 2008 | A1 |
| 20080032119 | Feldhahn et al. | Feb 2008 | A1 |
| 20080081077 | Faryniarz et al. | Apr 2008 | A1 |
| 20080112988 | Frank et al. | May 2008 | A1 |
| 20080125686 | Lo | May 2008 | A1 |
| 20080193427 | Kaesler et al. | Aug 2008 | A1 |
| 20080195033 | Eagleson et al. | Aug 2008 | A1 |
| 20080274065 | Robinson et al. | Nov 2008 | A1 |
| 20080286180 | Jones | Nov 2008 | A1 |
| 20080286212 | Cooley | Nov 2008 | A1 |
| 20080295843 | Haas | Dec 2008 | A1 |
| 20080299155 | McCook et al. | Dec 2008 | A1 |
| 20080311165 | Gabbay | Dec 2008 | A1 |
| 20080311218 | Oronsky et al. | Dec 2008 | A1 |
| 20080312583 | Oronsky et al. | Dec 2008 | A1 |
| 20080317836 | Dorogi et al. | Dec 2008 | A1 |
| 20090004294 | Margulies et al. | Jan 2009 | A1 |
| 20090018213 | Snyder et al. | Jan 2009 | A1 |
| 20090026083 | Shinji et al. | Jan 2009 | A1 |
| 20090148540 | Martin et al. | Jun 2009 | A1 |
| 20090163551 | Earnest | Jun 2009 | A1 |
| 20090186071 | Huey et al. | Jul 2009 | A1 |
| 20090246292 | Seville et al. | Oct 2009 | A1 |
| 20090287131 | Neron et al. | Nov 2009 | A1 |
| 20090304813 | Hickok | Dec 2009 | A1 |
| 20090311305 | Abbott et al. | Dec 2009 | A1 |
| 20100003198 | Stolmeier et al. | Jan 2010 | A1 |
| 20100015898 | An et al. | Jan 2010 | A1 |
| 20100055138 | Margulies et al. | Mar 2010 | A1 |
| 20100068161 | Todary Michael | Mar 2010 | A1 |
| 20100068297 | Naughton | Mar 2010 | A1 |
| 20100100188 | Fuller et al. | Apr 2010 | A1 |
| 20100158989 | Mentkow et al. | Jun 2010 | A1 |
| 20100228174 | Huey et al. | Sep 2010 | A1 |
| 20100233248 | Huey et al. | Sep 2010 | A1 |
| 20100307503 | Iwamoto et al. | Dec 2010 | A1 |
| 20110064826 | Spurge | Mar 2011 | A1 |
| 20110086088 | Berry | Apr 2011 | A1 |
| 20110195108 | Fujimori et al. | Aug 2011 | A1 |
| 20120063262 | Imran | Mar 2012 | A1 |
| 20120070476 | Moench | Mar 2012 | A1 |
| 20120071807 | McClure, Jr. | Mar 2012 | A1 |
| 20120071858 | Abbott et al. | Mar 2012 | A1 |
| 20120089068 | McClure, Jr. | Apr 2012 | A1 |
| 20130095184 | Lyczak et al. | Apr 2013 | A1 |
| 20130108670 | Lynch | May 2013 | A1 |
| 20130123716 | Abbott et al. | May 2013 | A1 |
| 20130226061 | Dickson | Aug 2013 | A1 |
| 20130039219 | Ratner | Nov 2013 | A1 |
| 20140005116 | Obayan et al. | Jan 2014 | A1 |
| 20140178313 | Okumura et al. | Jun 2014 | A1 |
| 20140221948 | Riesinger | Aug 2014 | A1 |
| 20140271495 | Abbott et al. | Sep 2014 | A1 |
| 20140271797 | Abbott et al. | Sep 2014 | A1 |
| 20140271798 | Abbott et al. | Sep 2014 | A1 |
| 20140271919 | Abbott et al. | Sep 2014 | A1 |
| 20160008272 | Abbott et al. | Jan 2016 | A1 |
| 20170000823 | Abbott et al. | Jan 2017 | A1 |
| 20170101699 | Moskovchenko et al. | Apr 2017 | A1 |
| 20180071206 | Abbott et al. | Mar 2018 | A1 |
| 20180133250 | Abbott et al. | May 2018 | A1 |
| 20190343732 | Mao et al. | Nov 2019 | A1 |
| 20190343876 | Abbott et al. | Nov 2019 | A1 |
| 20200206264 | Abbott et al. | Jul 2020 | A1 |
| 20200270723 | Abbott et al. | Aug 2020 | A1 |
| 20200281972 | Abbott et al. | Sep 2020 | A1 |
| 20210220397 | Abbott et al. | Jul 2021 | A1 |
| 20210220398 | Abbott et al. | Jul 2021 | A1 |
| 20210220399 | Abbott et al. | Jul 2021 | A1 |
| 20210228476 | Abbott et al. | Jul 2021 | A1 |
| 20230330137 | Abbott et al. | Oct 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 04029672 | Sep 1973 | AU |
| 2020201265 | Sep 2021 | AU |
| 2478137 | Feb 2006 | CA |
| 2912628 | Sep 2014 | CA |
| 3130099 | Aug 2020 | CA |
| 101203232 | Jun 2008 | CN |
| 101534823 | Sep 2009 | CN |
| 0115130 | Jan 1987 | EP |
| 1236461 | Sep 2002 | EP |
| 1627641 | Feb 2006 | EP |
| 3003046 | Apr 2016 | EP |
| 2762125 | Aug 2016 | EP |
| 2751544 | Jan 1998 | FR |
| 521215 | May 1940 | GB |
| 1333906 | Oct 1973 | GB |
| 1493750 | Nov 1977 | GB |
| 2449893 | Dec 2008 | GB |
| 3075995 | Mar 2001 | JP |
| 2003212765 | Jul 2003 | JP |
| 2010-265519 | Nov 2010 | JP |
| 2051154 | Dec 1995 | RU |
| 2155047 | Aug 2000 | RU |
| 1538101 | Jan 1990 | SU |
| WO-9215329 | Sep 1992 | WO |
| WO-9958095 | Nov 1999 | WO |
| WO-2001026665 | Apr 2001 | WO |
| WO-0239963 | May 2002 | WO |
| WO-0241862 | May 2002 | WO |
| WO-02096202 | Dec 2002 | WO |
| WO-2004073758 | Sep 2004 | WO |
| WO-2005072691 | Aug 2005 | WO |
| WO-2006096937 | Sep 2006 | WO |
| WO-2008037262 | Apr 2008 | WO |
| WO-2009042402 | Apr 2009 | WO |
| WO-2009088270 | Jul 2009 | WO |
| WO-2011069184 | Jun 2011 | WO |
| WO-2012063262 | May 2012 | WO |
| WO-2014150716 | Sep 2014 | WO |
| WO-2014150719 | Sep 2014 | WO |
| WO-2014151350 | Sep 2014 | WO |
| WO-2018052995 | Mar 2018 | WO |
| WO-2020171994 | Aug 2020 | WO |
| WO-2021222230 | Nov 2021 | WO |
| WO-2021236231 | Nov 2021 | WO |
| Entry |
|---|
| US 11,052,109 B2, 07/2021, Abbott et al. (withdrawn) |
| US 11,229,598 B2, 01/2022, Abbott et al. (withdrawn) |
| US 11,266,597 B2, 03/2022, Abbott et al. (withdrawn) |
| Shaligram, et al., “Toxicity of copper salts is dependent on solubility profile and cell type tested”, Toxicology in Vitro, 27(2):844-851, Mar. 2013, available online Dec. 31, 2012 (9 pages). |
| “VersaBase Cream, PCCA (RX): Ingredients and Reviews”, https://www.skinsafeproducts.com/versabase-cream-rx-pcca, accessed Jun. 3, 2022 (5 pages). |
| Horie, et al., “Inactivation and morphological changes of avian influenza virus by copper ions”, Arch Virol, 153:1467-1472, published online Jul. 1, 2008 (6 pages). |
| Prausnitz, et al., “Transdermal drug delivery”, Author Manuscript published in final edited form as Nat Biotechnol., 26(11):1261-1268, Nov. 2008 (18 pages). |
| Szunerits, et al., “Heat: A Highly Efficient Skin Enhancer for Transdermal Drug Delivery”, Frontiers in Bioengineering and Biotechnology, vol. 6, Article 15, Feb. 15, 2018 (13 pages). |
| Tuck, et al., “3.07—Corrosion of Copper and its Alloys”, Shreir's Corrosion, vol. 3, pp. 1937-1973, 2010 (38 pages). |
| Wright, Un-Spiked Results, Test ID: 05992-001-001, Version Type: Version, Sep. 12, 2017 (1 page). |
| “About the Study: Elvis COVID-19 Study Full Information”, The University of Edinburgh, URL <https://www.ed.ac.uk/usher/elvis-covid-19/about-the-study>, published Jun. 24, 2020 (4 pages). |
| “Copper(II) Sulfate, Pentahydrate”, ICSC 1416, CAS#: 7758-99-8, EC No. 231-847-6, International Labour Organization, World Health Organization, www.ilo.org/dyn/icsc/showcard.display?p_lang=en&p_card_id=1416&p_version=2, Oct. 2001 (2 pages). |
| Aaseth, J. et al., “Chapter 10: Copper (excerpt)”, from Handbook on the Toxicology of Metals, Second Edition, vol. II: Specific Metals, Friberg, et al., Eds., Elsevier Science Publishers B.V, Amsterdam, pp. 240-254, 1986 (19 pages). |
| “Coronavirus: Researchers to trial salt water as Covid-19 treatment”, URL <https://www.bbc.com/news/uk-scotland-edinburgh-east-fife-53170734>, Jun. 25, 2020 (2 pages). |
| Dutton, “Salt Water Vs. COVID-19: Researchers Launch Study to Lessen Symptoms and Duration of Illness”, URL <https://www.biospace.com/article/salt-water-vs-covid-19-scottish-researchers-launch-study-to-lessen-symptoms-and-duration-of-illness/>, BioSpace, Jun. 29, 2020 (6 pages). |
| EPA, “Drinking Water Criteria Document for Copper (Final Draft)”, United States Environmental Protection Agency, EPA-600/X-84-190-1, pages V-1 - V-28, Mar. 1985 (38 pages). |
| European Extended Search Report issued in European Application No. 20760320.0, dated Oct. 25, 2022 (17 pages). |
| European Extended Search Report issued in European Patent Application No. 14767738.9, dated Jan. 2, 2017 (8 pages). |
| Radulesco, et al., “Copper enhanced nasal saline irrigations: a safe potential treatment and protective factor for COVID-19 infection?”, Rhinology Online, 3:87-88, Jun. 6, 2020 (2 pages). |
| Stokinger, H.E. et al., “Chapter 11: Copper, Cu”, in Patty's Industrial Hygiene and Toxicology: vol. 2A—Toxicology, Clayton et al., Eds., John Wiley Sons, New York, pp. 1620-1630, 1981 (16 pages). |
| “CopperFixx Pain Relief Cream—Products”, URL:https://web.archive.org/web/20160905175719/http://copperfixx.com/index/php/copperfixx/products/copperfixx-pain-relief-cream.html, 2015, accessed Feb. 5, 2023 (2 pages). |
| “10 Homemade Gargles That Heal”, Reader's Digest of Canada, www.readersdigest.ca/health/conditions/gaggle-gargles/, Jan. 4, 2008 (3 pages). |
| “Antimicrobial Copper FAQs”, CDA Publication 201, Copper Development Association, Hemel Hempstead, United Kingdom, 2010 (8 pages). |
| “Assessment of the Safety and Efficacy of 3VM1001 Cream for Treatment of Chronic Pain Caused by Knee Osteoarthritis”, ClinicalTrials.gov, https://clinicaltrials.gov/ct2/history/NCT02332148?V_3, dated Aug. 19, 2015 (6 pages). |
| “Buffer Reference Center”, https://www.sigmaaldrich.com/life-science/core-bioreagents/biological-buffers/learning-center/buffer-reference-center.html, Oct. 26, 2008 (6 pages). |
| “Copper Sulfate”, extract from Extoxnet: Extension Toxicology Network, <http://pmep.cce.cornell.edu/profiles/extoxnet/carbaryl-dicrotophos/copper-sulfate-ext.html>, May 1994 (2 pages). |
| “Copper Sulphate's Role in Agriculture”, Excerpt from PAN Pesticides Database—Chemicals (1 page). |
| “Dangers of Copper Compounds (Sulfate, etc.)”, Pubchem.ncbi.nlm.nih.gov/compound/Copper_sulfate#section=Top, 2007 (17 pages). |
| “Difference Between 304 vs 316 Stainless Steel”, Eagle Stainless Tube & Fabrication, Inc., https://eagletube.com/about-us/news/304-vs-316-stainless-steel, Jun. 21, 2018 (2 pages). |
| “Lowering Infection Rates in Hospitals and Healthcare Facilities—The Role of Copper Alloys in Battling Infectious Organisms”, Copper, BioHealth Partnership Publication, Edition 1, Mar. 2007, 26 pages. |
| “New Molecular Test Available to Diagnose Trichomonas Vaginalis in Asymptomatic and Symptomatic Females”, PR Newswire, Oct. 18, 2012, 3 pages. |
| “Pelvic Inflammatory Disease (PID)”, CDC Fact Sheet, Centers for Disease Control, Dec. 12, 2012, 6 pages. |
| “Visual Analogue Scale”, https://web.archive.org/web/20150804080655/https://www.physio-pedia.com/Visual_Analogue_Scale, Aug. 4, 2015, accessed Dec. 13, 2017 (6 pages). |
| “WOMAC Osteoarthritis Index,” https://web.archive.org/web/20150907191904/https://www.physio-pedia.com/WOMAC_Osteoarthritis_Index, Sep. 7, 2015, accessed Dec. 13, 2017 (4 pages). |
| Al-Kharafi, et al., “Selective dissolution of brass in salt water”, Journal of Applied Electrochemistry, 34:47-53, 2004 (7 pages). |
| Amazon.com search for “Mouthwash”, https://www.amazon.com/s/ref=sr_nr_n_0?fst=p90x%3A1%2Cas%3Aoff&rh=n%3A3760911%2Cn%3A10079992011%2Cn%3A3778161%2Ck%3Amouthwash&keywords=mouthwash&ie=UTF8&qid=1502940655&rnid=11055981, dated Aug. 16, 2017 (11 pages). |
| Anthoni, J.F., “The Chemical Composition of Sea Water”, http://www.seafriends.org.nz/oceano/seawater.htm, accessed Jul. 28, 2016 (10 pages). |
| ASTM International, Designation: D1688-12, “Standard Test Methods for Copper in Water”, dated 2012, accessed Oct. 24, 2018 (10 pages). |
| AZO Materials, “Medical Applications of Stainless Steel 304 (UNS S30400)”, azom.com/Articles.aspx?=6641, Aug. 30, 2012 (3 pages). |
| Bauer, “Understanding radiation dermatitis”, American Nurse Today, 11(1):13-15, Jan. 2016 (3 pages). |
| Bauer, “Understanding radiation dermatitis”, URL<http://old.woundcareadvisor.com/understanding-radiation-dermatitis/>, Wound Care Advisor, vol. 5, No. 3, May/Jun. 2016 (6 pages). |
| Beigel, J.H. et al., “Remdesivir for the Treatment of Covid-19—Final Report”, The New England Journal of Medicine, 383(19):1813-1826, published online Oct. 9, 2020 (14 pages). |
| Ben-Hur, et al., “Phosphorus Burns: The Antidote: A New Approach”, British Journal of Plastic Surgery, 25:245-249, 1972 (5 pages). |
| Bianchetti, M. G., et al., “Body fluids and salt metabolism—Part I”, Italian Journal of Pediatrics, 35:36, Nov. 19, 2009 (6 pages). |
| Biocompatible, definition from Cambridge Dictionary, URL <https://dictionary.cambridge.org/us/dictionary/english/biocompatible>, accessed Oct. 26, 2020 (6 pages). |
| Blakley, B.R. “Overview of Copper Poisoning”, Merck Manual: Veterinary Manual, https://www.merckvetmanual.com/toxicology/copper-poisoning/overview-of-copper-poisoning, 2018 (3 pages). |
| Blanc, C. et al., “Galvanic coupling between copper and aluminium in a thin-layer cell”, Corrosion Science, 52(3):991-995, 2010 (6 Pages). |
| Borkow, G. et al., “Copper as a Biocidal Tool”, Current Medicinal Chemistry, 12:2163-2175 (2005) (13 pages). |
| Cancer Facts & Figures 2016, American Cancer Society, URL <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.html>, 2016 (72 pages). |
| Cao, “Man Sperm Self Report”, Harbin Publishing House, p. 27, Mar. 2012 (2 pages)—with English Translation. |
| CDA Research Group, Inc., “A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Tolerability of 3VM1001 Cream for the Treatment of Pain Associated With Post-Herpetic Neuralgia: A Proof of Concept Study”, Identifier NCT03421613, published on clinicaltrials.gov <URL: https://www.clinicaltrials.gov/ct2/show/NCT03421613>, published Jul. 10, 2018 (8 pages). |
| CDA Research Group, Inc., “A Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 3VM1001 Cream for the Treatment of Chronic Pain Caused by Osteoarthritis of the Knee: A Proof of Concept Study”, Identifier: NCT02332148, Published on ClinicalTrials.Gov, <URL: https://clinicaltrials.gov/ct2/show/NCT02332148>, Published Aug. 21, 2015 according to ClinicalTrials.Gov (6 pages). |
| CDA Research Group, Inc., “A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of 3VM1001 Cream for the Treatment of Chronic Pain Caused by Osteoarthritis of the Knee: A Dose Ranging Study”, Identifier: NCT03142178 published on clinicaltrials.gov <URL: https://www.clinicaltrials.gov/ct2/show/ NCT03142178 >, published Jul. 6, 2018 according to ClinicalTrials.Gov (9 pages). |
| CDA Research Group, Inc., “Assessment of the Safety and Efficacy of 3VM1001 Cream for Treatment of Chronic Pain Caused by Knee Osteoarthritis”, U.S. National Library of Medicine, Clinical Trial NCT02332148, https://clinicaltrials.gov/ct2/show/NCT02332148, Aug. 21, 2015, accessed Dec. 12, 2017 (5 pages). |
| Centers for Disease Control, “CDC No Longer Recommends Oral Drug for Gonorrhea Treatment”, Press Release, Aug. 9, 2012, 1 page. |
| Centers for Disease Control. “Pelvic Inflammatory Disease (PID)”, CDC Fact Sheet, Dec. 12, 2012, 6 pages. |
| Collins, Reflections of Dentifrice Ingredients, Benefits and Recommendations: A Peer-Reviewed Publication, www.ineedce.com, accessed https://www.dentalacademyofce.com/courses/2086/pdf/1103cei_dentifrices_web.pdf, Oct. 2009 (11 pages). |
| Copper Gluconate, except from Wikipedia, https://en.wikipedia.org/wiki/Copper_gluconate, Mar. 29, 2017 (1 page). |
| Copper Glycinate Product Data Sheet, https://www.lookchem.com/Copper-glycinate/, dated 2008, accessed Aug. 30, 2018 (2 pages). |
| Cortes, et al., “The use of copper to help prevent transmission of SARS-coronavirus and influenza viruses. A general review”, Diagnostic Microbiology and Infectious Disease, 98:115176, available online Aug. 15, 2020 (5 pages). |
| Database WPI, Week 199640, Thompson Scientific, London GB, AN 1996-400647, XP002765918, 1996 (2 pages). |
| Database WPI, Week 200375, Thompson Scientific, AN 2003-793474, XP002767346, 2003 (2 pages). |
| De Rauglaudre, G. et al., “Tolerance of the association sucralfate / Cu—Zn salts in radiation dermatitis”, Annales de dermatologie, 1:11-15 (2008)—English Abstract (5 pages). |
| Dispose—definition, https://www.merriam-webster.com/dictionary/dispose, downloaded Jun. 24, 2018 (1 page). |
| Dragani, R. “Does Salt Change the pH of Water?”, https://sciencing.com/does-salt-change-ph-water-4577912.html., downloaded Dec. 31, 2019, Apr. 19, 2018 (3 pages). |
| Duguid, R., “Copper-inhibition of the growth of oral streptococci and actinomyces”, Biomaterials, 4:225-227, Jul. 1983 (3 pages). |
| Edematous—Definition from The Medical Dictionary of the Free Dictionary Online, https://medical-dictionary.thefreedictionary.com/edematous, accessed Mar. 7, 2018 (7 pages). |
| European Extended Search Report issued in EP14767396.6, dated Feb. 9, 2017 (10 pages). |
| European Extended Search Report issued in EP14768757.8, dated Dec. 6, 2016 (9 pages). |
| European Extended Search Report issued in EP14768896.4, dated Feb. 27, 2017 (8 pages). |
| European Extended Search Report issued in EP20185469.2, dated Oct. 9, 2020 (10 pages). |
| European Extended Search Report issued in European Patent Application No. EP20161252.0, dated Jun. 17, 2020 (9 pages). |
| European Extended Search Report, issued in European Patent Application No. 17851454.3, dated Jul. 10, 2020 (14 pages). |
| European Partial Supplementary Search Report issued in EP17851454.3, dated Apr. 6, 2020 (14 pages). |
| Extended European Search Report issued in EP14767738.9, dated Jan. 2, 2017 (8 pages). |
| Faltermeier, R. B., “The Evaluation of Corrosion Inhibitors for Application to Copper and Copper Alloy Archaeological Artefacts”, Thesis Submitted for the Degree of Doctor of Philosophy in the Faculty of Science of the University of London, Department of Conservation and Museum Studies, Institute of Archaeology, University College London, University of London, Jul. 1995 (332 pages). |
| Fenelon, A.M. et al., “The electrochemical synthesis of polypyrrole at a copper electrode: corrosion protection properties”, Electrochimica Acta, 47:4467-4476, 2002 (10 pages). |
| Gerasimov, V. V. et al., “Effect of Temperature on the Rate of Corrosion of Metals”, Russian Chemical Bulleting, pp. 1192-1197, Oct. 6, 1957 (6 pages). |
| Google Search “Copper Salt for Sore Throat ‘Coronavirus’”, URL https://www.google.com/search?source=hp&ei=YhxEX5fdBvOuytMPmca9cAo&q=coppe . . . >,, dated Aug. 24, 2020 (2 pages). |
| Google Search, “copper in sea salt”, URL <https://www.google.com/search?q=copper+in+sea+salt&ei=TRrWYJyaCemr5NoPvlmPiA . . . >, accessed Jun. 25, 2021 (2 pages). |
| Google Search, “Copper phosphate buffered saline”, URL: <https://scholar.google.com/scholar?hl=en&as_sdt=0%2C47&q=copper=+phosphate+buffered . . . >, accessed Aug. 5, 2021 (2 pages). |
| Google Search, “dead sea salt and acetate buffer mouthwash”, URL <https://www.google.com/search?q=dead+sea+salt+and+acetate+buffer+mouthwash&ei=d . . . >, accessed Jun. 25, 2021 (2 pages). |
| Google Search, “mouthwash dead sea salt and acetate buffer”, URL <https://google.com/search?q=mouthwash+dead+sea+salt+and+acetate+buffer&tbm=. . . >, accessed Jun. 25, 2021 (2 pages). |
| Gray, L.W. et al., “Urinary Copper Elevation in a Mouse Model of Wilson's Disease Is a Regulated Process to Specifically Decrease the Hepatic Copper Load”, PLoS One, 7(6):e38327, Jun. 22, 2012 (11 pages). |
| Higdon, J. et al., “Copper”, Linus Pauling Institute, Oregon State University, Apr. 2003, 8 pages. |
| International Search Report and Written Opinion issued by the U.S. Patent and Trademark Office as International Searching Authority, in International Application No. PCT/US21/24555, dated Jul. 8, 2021 (9 pages). |
| International Search Report and Written Opinion issued by the U.S. Patent and Trademark Office as International Searching Authority, issued in International Application No. PCT/US2020/17454, dated Jun. 23, 2020 (12 pages). |
| International Search Report and Written Opinion issued by U.S. Patent and Trademark Office as International Searching Authority, in International Application No. PCT/US17/51356, Jan. 18, 2018 (11 pages). |
| Ion, Wikipedia, https://en.wikipedia.org/wiki/Ion, accessed Aug. 30, 2018 (11 pages). |
| Iqbal, K. et al., “Role of Different Ingredients of Tooth Pastes and Mouthwashes in Oral Health”, Journal of the Pakistan Dental Association, 20(03):163-170, Jul.-Sep. 2011 (8 pages). |
| Khaled, K.F., “Studies of the corrosion inhibition of copper in sodium chloride solutions using chemical and electrochemical measurements”, Materials Chemistry and Physics, 125:427-433, 2011 (7 pages). |
| Kirkpatrick, K., “Does saltwater work as mouthwash?”, http://health.howstuffworks.com/wellness/oral-care/products/saltwater-as-mouthwash.htm, available online Sep. 18, 2011, accessed Mar. 4, 2019 (6 pages). |
| Kole, A., et al., “Acute radiation dermatitis in breast cancer patients: challenges and solutions”, Breast Cancer—Targets and Therapy, 9:313-323, May 5, 2017 (11 pages). |
| Leventhal, J., et al., “Radiation Dermatitis: Recognition, Prevention, and Management”, Oncology (Williston Park), 31(12):885-887, 894-899, Dec. 15, 2017 (10 pages). |
| Lindeburg, M.R., Chemical Engineering Reference Manual for the PE Exam, Seventh Edition, Professional Publications, Inc., Belmont, California, p. 20-10, 2013 (3 pages). |
| Malik, R. “Warm Saline Rinses”, http://www.nature.com/articles/sj.bdj.2009.1093.pdf, accessed Dec. 31, 2019, Br. Dental J., 207(11):520, 2009 (2 page). |
| Maltz, M. et al., “Effect of copper fluoride and copper sulfate on dental plaque, Streptococcus mutans and caries in hamsters”, Scand. J. Dent. Res., 96:390-392, Oct. 1, 1988 (3 pages). |
| Marques, M.R.C. et al., “Simulated Biological Fluids with Possible Application in Dissolution Testing”, Dissolution Technologies, 18(3):15-28, Aug. 2011 (14 pages). |
| Metikoš-Huković, M. et al., “Copper Corrosion at Various pH Values with and without the Inhibitor”, Journal of Applied Electrochemistry, 30:617-624, 2000 (8 pages). |
| Michels, H.T. et al., “Copper Alloys for Human Infectious Disease Control”, presented at Material Sciences and Technology Conference, Copper for the 21st Century Symposium, Pittsburgh, PA, Sep. 25-28, 2005, 11 pages. |
| Moore, R.L. et al., “Evaluating the Anti-Plaque Capabilities of a Copper-Containing Prophylaxis Paste”, J. Periodontal., 60(2):78-80, Feb. 1989 (3 pages). |
| Mulligan, A.M. et al., “The effect of increasing copper content in phosphate-based glasses on biofilms of Streptococcus sanguis”, Biomaterials, 24:1797-1807, 2003 (11 pages). |
| Nkonzo, N., “Antimicrobial Copper”, International Copper Association, Copper Development Association, May 5, 2010, 6 pages. |
| Owen, D.H. et al., “A Vaginal Fluid Simulant”, Contraception, 59(2):91-95, Feb. 1999 (5 pages). |
| Perrie, Y. et al., “Chapter 1: Controlling Drug Delivery”, FASTtrack: Pharmaceutics—Drug Delivery and Targeting, Second Edition, Sample Chapter, 14, Jun. 2012 (26 pages). |
| Physiological Saline, definition from APA Dictionary of Psychology,, <URL: https://dictionary.apa.org/physiological-saline[Oct. 5, 2021 11:47:23 AM], 1 page. |
| Pramanik, et al., “A novel study of antibacterial activity of copper iodide nanoparticle mediated by DNA and membrane damage”, Colloids and Surfaces B: Biointerfaces, 96:50-55, published online Apr. 5, 2012 (6 pages). |
| Ramachandran, S. et al., “Gluconic Acid: Properties, Applications and Microbial Production”, Food Technol. Biotechnol., 44(2):185-195, 2006 (11 pages). |
| Read, A.J., “Dissolution of Copper in Weakly Acidic Solutions”, The Journal of Physical Chemistry, 76(24):3656-3663, 1972 (8 pages). |
| Robinson, J., “No improvement in mortality rates for COVID-19 patients treated with remdesivir”, the Pharmaceutical Journal, DOI:10.1211/PJ.2020.20208045, published online Jun. 8, 2020 (3 pages). |
| Roldan, S, et al., “Biofilms and the tongue: therapeutical approaches for the control of halitosis”, Clin. Oral Invest., 7:189-197, 2003 (9 pages). |
| Rosenhein, L.D., “The Household Chemistry of Cleaning Pennies”, Applications and Analogies, Journal of Chemical Education, 78(4):513-515, Apr. 2001 (3 pages). |
| Ryan, J., “Ionizing Radiation: The Good, the Bad, and the Ugly”, Author Manuscript published in final edited form as J Invest Dermatol., 132(3 0 2):985-993, Mar. 2012 (16 pages). |
| Ryan, J., et al., “Curcumin for Radiation Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Thirty Breast Cancer Patients”, Author Manuscript published in final edited form as Radiat Res., 180(1):34-43, Jul. 2013 (20 pages). |
| Sawyer, D.T., “Metal-Gluconate Complexes”, Chem. Rev., 64(6):633-643, 1964 (11 pages). |
| Saxer, U P et al., “New Studies on Estimated and Actual Toothbrushing Times and Dentifrice Use”, J. Clin. Dent., 9(2):49-51, 1998 (1 page)—Abstract Only. |
| Shackel, N.A. et al., “Copper-salicylate gel for pain relief in osteoarthritis: a randomised controlled trial”, MJA, 167:134-136, Aug. 4, 1997 (3 pages). |
| Sims, “‘Breast Cancer Isn't Sexy’: Woman Shares Post-Radiation Images to Show Reality of Disease”, The Independent, <URL: https://www.independent.co.uk/life-style/health-and-families/health-news/breast-cancer-isn-t-sexy-woman-shares-postradiation-images-to-show-reality-of-disease-a6709516.html>, Oct. 26, 2015 (4 pages). |
| Solioz, “Dry Copper Kills Bacteria on Contact”, Science Daily, Feb. 22, 2011, 4 pages. |
| Stein, “Gonorrhea Evades Antibiotics, Leaving Only One Drug to Treat Disease”, www.npr.org/blogs/health, Aug. 10, 2012, 5 pages. |
| Stein, R., “Gonorrhea Evades Antibiotics, Leaving Only One Drug to Treat Disease”, www.npr.org/blogs/health, Aug. 10, 2012, 5 pages. |
| Tamba, B.I. et al., “Common Trace Elements Alleviate Pain in an Experimental Mouse Model”, Journal of Neuroscience Research, 91:554-561, 2013 (8 pages). |
| VersaBase Cream, Product Information Document, from PCCA, https://pccarx.com/Products/ProductCatalog?pid=30-3641, accessed Dec. 31, 2019 (4 pages). |
| Wang, et al., “Family Planning Technology”, Shanghai Science and Technology Press, p. 334, Dec. 31, 1997 (2 pages)—English Excerpt. |
| Wikipedia, “Acetic acid”, https://en.wikipedia.org/wiki/Acetic_acid, accessed Oct. 14, 2019 (19 pages). |
| Wikipedia, “Buffer Solution”, Wikipedia, the Free Encyclopedia, https://en.wikipedia.org/wiki/Buffer_Solution, accessed Apr. 7, 2017 (8 pages). |
| Wikipedia, “Copper(I) chloride”, https://en.wikipedia.org/wiki/Copper(I)_chloride, accessed Oct. 13, 2019 (8 pages). |
| Wikipedia, “Saline (Medicine)”, URL <https://en.wikipedia.org/wiki/Saline_(medicine)>, accessed Jul. 21, 2021 (9 pages). |
| Wikipedia, “Salt (chemistry)”, https://en.wikipedia.org/wiki/Salt_(chemistry), accessed Oct. 14, 2019 (6 pages). |
| Wikipedia, “Suspension (chemistry)”, https://en.wikipedia.org/wiki/Suspension_(chemistry), accessed Oct. 13, 2019 (3 pages). |
| Williams, M., et al., “Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity”, I. J. Radiation Oncology Biology Physics, 36(2):345-349, Sep. 1, 1996 (5 pages). |
| Wong, R. K. S. et al., “Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group”, Support Care Cancer, DOI 10.1007/s00520-013-1896-2, published online Aug. 14, 2013 (16 pages). |
| Yassin, N. et al., “Effect of a topical copper indomethacin gel on inflammatory parameters in a rat model of osteoarthritis”, Drug Design, Development and Therapy, 9:1491-1498, 2015 (8 pages). |
| Zatcoff, R.C. et al., “Treatment of tinea pedis with socks containing copper-oxide impregnated fibers”, The Foot, 18:136-141 (2008) (6 pages). |
| Zwirner, E., “5 Advantages of Vertical Storage Tanks”, https://www.zwirnerequipment.com/blog/5-advantages-vertical-storage-tanks/, Oct. 20, 2014 (2 pages). |
| Khan, “Taanbey-ka-Kushta”, Traditional Knowledge Resource, Traditional Knowledge and Digital Library, Khazaain-al-Advia, vol. II (20th Century Ghani AD), Nadeem Yunus Printer, Sheikh Mohd Basheer & Sons, Lahore, pp. 155-156, 1911 (4 pages). |
| Madanapala, “Tamra Guna”, Traditional Knowledge Resource, Traditional Knowledge and Digital Library, Translated by Rama Prasad, Khemaraj Shri Krishnadas, Prakashan, Bombay, India, p. 98, 1998 (4 pages). |
| “Can copper supplements fight COVID-19?”, Based on Science, https://www.nationalacademies.org/based-on-science/covid-19-copper, National Academies Sciences Engineering Medicine, updated Jul. 5, 2023 (3 pages). |
| “Chapter 11.7: Crystalline Solids; Crystal Lattices and Unit Cells”, in General Chemistry, Ninth Edition, Eds., Ebbing, et al., Houghton Mifflin Company, Boston, pp. 448-450, 2009 (19 pages). |
| “Study: To determine the anti-viral efficacy of 3VM-1000 suspension in K18-hACE2 transgenic mice model of SARS-CoV-2 infection”, Texas Biomedical Research Institute, Study Sponsor 3V Medical Research Group, Inc., May 4, 2021 (10 pages). |
| Abbott, et al., “Statement of Work (SOW): In Vitro Assessment of the Effect of 3VM1000 Suspension on SARS-CoV-2 Infectivity”, Texas Biomedical Research Institute, Jul. 22, 2020 (3 pages). |
| Correspondence from Dominic Abbott, 3V Medical Research Group, to Varun Dwivedi, Subject: Respiratory Drug & Development, includes attachment of Drug Development and Delivery ebook, email dated Jun. 27, 2022 (1 page). |
| Drug Development & Delivery, eBook, Respiratory Drug Development Edition, Summer 2021 (14 pages). |
| Dwivedi, et al., “Final Report: In vitro assessment of the effect of 3VM-1000 suspension on SARS-CoV-2 Infectivity”, Texas Biomedical Research Institute, Study Sponsor 3V Medical Research Group, Inc., May 13, 2021 (14 pages). |
| European Search Report issued in European Application No. EP21807576.0 dated Jan. 31, 2024 (10 pages). |
| Glaser, et al., “Pilot Study: Absorption and Efficacy of Multiple Hormones Delivered in a Single Cream Applied to the Mucous Membranes of the Labia and Vagina”, Gynecologic Obstetric Investigation, 66:111-118, published online Apr. 29, 2008 (8 pages). |
| Kulkarni, “Study: To determine the anti-SARS-CoV-2 effect of 3VM-1000 suspension in K18 hACE-2 mice (SOW-20-375)”, Texas Biomedical Research Institute, Study Sponsor 3V Medical Research Group, Inc., dated Dec. 15, 2022 (54 pages). |
| Raha, et al., “Is copper beneficial for COVID-19 patients?”, Medical Hypotheses, vol. 142, https://doi.org/10.1016/j.mehy.2020.109814, 2020 (3 pages). |
| Trace Minerals Ionic Copper Liquid 3mg, https://bigvits.co.uk/trace-minerals-ionic-copper-liquid-3mg-2-fl-oz-59ml.html?utm_source=google_shopping&gad_source=1&gclid=EAlalQobChMly_7_1fyXhQMVol1QBh2hCwiJEAQYFSABEgKn5fD_BwE, Jul. 19, 2022 (6 pages). |
| Abdel-Mottaleb, et al., “In search for effective and safe drugs against SARS-CoV-2: Part II] The role of selected salts and organometallics of copper, zinc, selenium, and iodine food supplements”, ChemRxiv, doi: 10.26434/chemrxiv.12234743.v1, available May 5, 2020 (13 pages). |
| Gordon, “Divalent Copper Compounds as Inhibitory Agents of Influenza A”, Thesis submitted to the faculty of Brigham Young University, Department of Physiology and Development Biology, https://scholarsarchive.byu.edu/etd/6248, Jun. 2014 (24 pages). |
| Number | Date | Country | |
|---|---|---|---|
| 20220226235 A1 | Jul 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13841992 | Mar 2013 | US |
| Child | 17712764 | US |
